Berengere Macabeo

Boulogne-billancourt, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.

Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.

Journal: ESMO open

Published: March 21, 2025

Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.

Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.

Journal: Journal of medical economics

Published: May 10, 2024

Methods for Indirect Treatment Comparison: Results from a Systematic Literature Review.

Methods for Indirect Treatment Comparison: Results from a Systematic Literature Review.

Journal: Journal of market access & health policy

Published: October 27, 2023

The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain.

The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain.

Journal: PharmacoEconomics - open

Published: October 26, 2023

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement.

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement.

Journal: Journal of market access & health policy

Published: June 16, 2023

Erratum to "Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis" [Cancer Treat. Rev. 110 (2022) 102463].

Erratum to "Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis" [Cancer Treat. Rev. 110 (2022) 102463].

Journal: Cancer treatment reviews

Published: December 11, 2022

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.

Journal: BMJ open

Published: November 21, 2022

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.

Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma.

Journal: The European journal of health economics : HEPAC : health economics in prevention and care

Published: November 04, 2022

Response to 'considerations regarding a network meta-analysis of targeted therapies for BRAF mutant unresectable or metastatic melanoma'.

Response to 'considerations regarding a network meta-analysis of targeted therapies for BRAF mutant unresectable or metastatic melanoma'.

Journal: Cancer treatment reviews

Published: October 14, 2022

Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.

Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.

Journal: Cancer treatment reviews

Published: May 27, 2022

A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.

A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.

Journal: Expert review of vaccines

Published: May 03, 2017

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.

Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America.

Journal: Human vaccines & immunotherapeutics

Published: January 25, 2017

Showing 1-12 of 18

Last Updated: 09/26/2026